Price
$133.72-14.53%Social Signal Score
Analyst Ratings
38 analysts52-week range
- Last close
- $133.72
- Off 52w high
- -14.5%
- 200-day average
- $129.22
- vs 200-day
- +3.5%
Revenue
$18.09B+78.79%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Davis
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 74,000
- Beta
- 0.22
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 3.70
Financials
Revenue
$18.09B+78.8%Net Income
$5.07BEBITDA
$6.11BFree Cash Flow
$5.52B+79.1%EPS (diluted)
$2.04Shares Outstanding (diluted)
2.48B-10.6%Operating Expenses
$7.42BCash & Debt
$9.65BReturn of Capital
$2.75BRevenue by Segment (annual)
$65.01BDividend per Share
$0.88Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $64.93B | $18.25B | $7.30 |
| 2024 | $64.17B | $17.12B | $6.76 |
| 2023 | $60.12B | $365.00M | $0.14 |
| 2022 | $59.28B | $14.52B | $5.73 |
| 2021 | $48.70B | $13.05B | $5.16 |
| 2020 | $41.52B | $7.07B | $2.79 |
| 2019 | $39.12B | $9.84B | $3.84 |
| 2018 | $42.29B | $6.22B | $2.40 |
| 2017 | $40.12B | $2.39B | $0.95 |
| 2016 | $39.81B | $3.92B | $2.07 |
| 2015 | $39.50B | $4.44B | $1.60 |
| 2014 | $42.24B | $11.92B | $4.20 |
| 2013 | $44.03B | $4.40B | $1.50 |
| 2012 | $47.27B | $6.17B | $2.20 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MRK's reported EPS growth of 9.7% a year over 13 years.
- EPS in 5 years
- $11.59
- Implied price
- $162.27
- Return from $133.72
- 3.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $80.68 — -39.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| -0.3% | -11.7% | -8.4% | -5.5% | -3.0% | -0.7% |
| 4.7% | -7.2% | -3.8% | -0.8% | 1.9% | 4.3% |
| 9.7% | -2.8% | 0.8% | 3.9% | 6.8% | 9.3% |
| 14.7% | 1.6% | 5.4% | 8.7% | 11.6% | 14.3% |
| 19.7% | 6.0% | 10.0% | 13.4% | 16.5% | 19.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
57-17.82%Social Signal Score
Mentions (100)
- Newsdefenseworld.net·1d ago·Neutral
Top Pharmaceutical Stocks To Add to Your Watchlist – November 19th Eli Lilly and Company, Insmed, Johnson and Johnson, Merck and Co., Inc., AbbVie, Pfizer, and SELLAS Life Sciences Group are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell prescription and other medicines. For investors, they offer exposure to
View source ↗ - Newsreuters.com·2d ago·Negative
Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial
View source ↗ - News (RSS)seekingalpha·3d ago·Negative
Merck inks cancer research deal with AI drug discovery firm Isomorphic Labs
View source ↗ - Newszacks.com·3d ago·Neutral
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsseekingalpha.com·3d ago·Positive
Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference Transcript Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·3d ago·Neutral
Merck & Co. Eyes Kidney Cancer Data as Vaccine Research Expands Beyond Melanoma Merck & Co., Inc. NYSE: MRK is studying how its experimental personalized cancer vaccine might work across different tumor types, with kidney cancer data expected to help determine whether the approach can extend beyond tumors with a high number of mutations, a company executive said at the Jefferies Healthcare Conference.
View source ↗ - Newsbusinesswire.com·3d ago·Neutral
Merck and Isomorphic Labs Enter Strategic Research Collaboration RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a research collaboration that brings together Isomorphic Labs' AI approach to drug discovery with Merck's rich proprietary data resources and deep discovery experience. The companies will collaborate to discover therapeutic small molecule candid…
View source ↗ - News (RSS)zerohedge·3d ago·Negative
The Fake 96,000-Patient Database That Sank Hydroxychloroquine... And Medicine's Growing Black-Box The Fake 96,000-Patient Database That Sank Hydroxychloroquine... And Medicine's Growing Black-Box Authored by Maryanne Demasi via Brownstone Institute,On May 22, 2020, the Lancet published a study that changed the course of the Covid-19 pandemic.It purported to analyze the medical records of 96,032 patients hospitalized with Covid-19 across 671 hospitals and six continents, delivering a damning conc
View source ↗ - 4chan /biz/biz·4d ago·Positive
>>62921512>>62921498 >You could just buy the top holdings with no fee. Click on the tab that says holdings. Symbol Company % Assets TXN Texas Instruments Incorporated 4.58% COP ConocoPhillips 4.35% CVX Chevron Corporation 4.31% PG The Procter & Gamble Company 4.24% KO The Coca-Cola Company 4.13% AMGN Amgen Inc. 4.08% HD The Home Depot, Inc. 4.01% UNH UnitedHealth Group Incorporated 3.95% MRK Merck & Co., Inc. 3.82% PEP PepsiCo, Inc. 3.79%
View source ↗ - PodcastAll In·5d ago·Negative
with Regeneron where they found the actual genome responsible chronic liver disease using the delivery, because their researchers there and actually came up with drugs for that. That's confusing. In our decade, if you were to take the claim, we had Dario make any chance that like we cure cancer in the next 10 years. That's a pretty bold statement. It's very hard for me to say, I don't know exactly what's needed. I mean, I think progress will be faster, but for a lot of these things, it also has
View source ↗ - Newsfool.com·6d ago·Positive
Is Merck's Stock Still a Good Buy at $150? Merck is coming off a strong quarter as revenue from a new version of Keytruda boosted its top line. It remains likely, however, that its revenue will drop off in the near future as key patents on Keytruda are expiring in the near future.
View source ↗ - News247wallst.com·8d ago·Neutral
He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment A retiree on Original Medicare finishes melanoma surgery and hears about a personalized vaccine that could cut his odds of relapse. Whether he can get it, and who pays for what, hinges on a little-known coverage rule.
View source ↗ - Newsbusinesswire.com·9d ago·Neutral
…lesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of an expanded indication for ENFLONSIA® (clesrovimab) to include prevention of …
View source ↗ - Newsbusinesswire.com·9d ago·Neutral
… Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG® (belzutifan), Merck's first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhi…
View source ↗ - News (RSS)wsj·10d ago·Neutral
Health Care Roundup: Market Talk Find insight on Moderna, Merck KGaA and more in the latest Market Talks covering the health care sector.
View source ↗ - News (RSS)seekingalpha·10d ago·Neutral
Merck KGaA raises 2026 outlook as Bio-Techne deal nears completion
View source ↗ - News (RSS)investing·10d ago·Positive
Merck KGaA Q3 2026 slides: strong beat, raised guidance, shares fall
View source ↗ - News (RSS)zerohedge·10d ago·Neutral
Nasdaq Futures Slide As Nvidia Board Hunts For Huang's Replacement, Rivals Feast Nasdaq Futures Slide As Nvidia Board Hunts For Huang's Replacement, Rivals Feast US futures are lower, led by a slide in Nasdaq contracts, after Nvidia's board started hunting for a replacement for Jensen Huang following reports of multiple extramarital affairs, including one with an alleged Chinese spy, turning the AI trade's central bank into its biggest single risk; meanwhile the haven bid sent long-end Treasurie
View source ↗ - Newsmarketbeat.com·10d ago·Neutral
What Merck KGaA (MRK) Said on Its Q3 Earnings Call Merck KGaA ETR: MRK raised its full-year 2026 outlook for the third time after faster third-quarter sales growth in its Life Science and Electronics businesses offset pressure on its Healthcare portfolio.
View source ↗ - News (RSS)rte·10d ago·Negative
Germany's Merck raises 2026 guidance for third time German drugmaker Merck has today raised its 2026 core profit guidance for the third time this year, helped by better underlying performance, foreign exchange effects and the acquisition of US firm Bio-Techne.
View source ↗ - Newszacks.com·13d ago·Neutral
MRK's 2027 Outlook Challenging, Long-Term Prospects Promising Merck's 2027 growth faces generic pressures, vaccine weakness and Keytruda slowdown, but its expanding pipeline offers promising long-term potential.
View source ↗ - Newszacks.com·16d ago·Neutral
Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold? MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.
View source ↗ - Newszacks.com·17d ago·Neutral
MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last? Merck's Keytruda and Gardasil sales rise in Q3, but inventory reversals, slowing demand and looming competition could challenge growth.
View source ↗ - News247wallst.com·19d ago·Positive
Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue. Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything.
View source ↗ - Newsbusinesswire.com·20d ago·Neutral
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026 RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN.
View source ↗ - News (RSS)seekingalpha·21d ago·Neutral
Notable healthcare headlines for the week: Eli Lilly, Merck, and AstraZeneca in focus
View source ↗ - News (RSS)thestreet·21d ago·Neutral
Merck stock rises as its cancer strategy gets personal A personalized melanoma vaccine could prevent recurrence and fuel Merck’s growth.
View source ↗ - Newsfool.com·23d ago·Negative
Why Merck Stock Flew Higher on Friday The company easily beat analyst estimates for both revenue and net income. Market players didn't seem overly worried about the future of its top drug.
View source ↗ - Newsbenzinga.com·23d ago·Positive
Merck One of Top Large-Cap Biopharma Picks-Analyst Merck & Co. Inc. (NYSE:MRK) shares were trading higher on Friday on a continued rally on better-than-expected third-quarter earnings and upbeat fiscal 2026 guidance.
View source ↗ - Newszacks.com·23d ago·Neutral
Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook MRK raises its 2026 outlook as KEYTRUDA demand, newer medicines and oncology pipeline breakthroughs support growth despite looming patent and generic pressures.
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
Merck & Co., Inc. Q3 Earnings Call Highlights Merck & Co., Inc. NYSE: MRK reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic products and animal health helped offset product-specific and market headwinds.
View source ↗ - News (Marketaux)dividend-growth-stocks.com·23d ago·Neutral
Merck & Co., Inc. (MRK) Dividend Stock Analysis Merck & Co., Inc. (MRK) Dividend Stock Analysis
View source ↗ - News (RSS)investing·24d ago·Negative
Merck to boost next decade revenue forecast on new drugs optimism
View source ↗ - Newsfool.com·24d ago·Negative
Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction Newer drugs are scaling fast enough to offset generic losses. Merck's third-quarter sales rose 5% to about $18.1 billion, but roughly $550 million of that came from the timing of customer purchases, so underlying growth was close to flat.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Merck & Co., Inc. (MRK) Q3 2026 Earnings Call Transcript Merck & Co., Inc. (MRK) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·24d ago·Positive
MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up Merck's Q3 earnings and sales beat estimates as Keytruda and newer products drive growth, prompting the company to raise its 2026 earnings outlook.
View source ↗ - News (RSS)zerohedge·24d ago·Neutral
Tech Futures Tumble As Alphabet Plunges, Small Caps Rise Ahead Of PCE, ECB Tech Futures Tumble As Alphabet Plunges, Small Caps Rise Ahead Of PCE, ECB US futures are lower, with Nasdaq contracts sliding as Alphabet's ugly search miss revived the "is AI capex paying off" debate, while Microsoft's Azure beat and lighter capex, a roughly 1% drop in oil on fresh US-Iran diplomacy chatter and news that Christine Lagarde will quit the ECB nine months early round out the morning's drivers; as a result s
View source ↗ - News247wallst.com·24d ago·Negative
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Merck: A Strong Quarter, But It's Time To Take A Step Back In the third quarter, Merck & Co., Inc.'s revenue grew 8.9% QoQ. Sales of Keytruda+Keytruda Qlex, its PD-1 immune checkpoint inhibitors, reached $8.1 billion, up 5.6% YoY and 2.8% QoQ. Winrevair, its activin signaling inhibitor for pulmonary arterial hypertension, also performed well, generating $694 million in net revenue, up 18% sequentially.
View source ↗ - Newszacks.com·24d ago·Positive
Merck (MRK) Surpasses Q3 Earnings and Revenue Estimates Merck (MRK) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $2.58 per share a year ago.
View source ↗ - Newswsj.com·24d ago·Negative
Merck Revenue Up on Keytruda, Winrevair Growth Third-quarter profit came in at $5.07 billion, or $2.04 a share, compared with $5.79 billion, or $2.32 a share, a year earlier.
View source ↗ - Newscnbc.com·24d ago·Negative
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength Merck topped third-quarter estimates and hiked its adjusted profit outlook. The company's immunotherapy Keytruda, including a newer injectable form of the drug called Qlex, posted stronger-than-expected sales.
View source ↗ - Newsbarrons.com·24d ago·Negative
Merck Earnings Blow Past Estimates. Why Wall Street Is Looking Past the Numbers. Merck is leaning on newer drugs and the promise of its pipeline assets as a patent cliff looms for its largest revenue driver, Keytruda.
View source ↗ - Newszacks.com·25d ago·Neutral
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
View source ↗ - Newszacks.com·26d ago·Negative
Is Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings? MRK heads into Q3 earnings with strong Keytruda sales and new drug growth, but declining estimates, Gardasil weakness and looming patent risks cloud its outlook.
View source ↗ - News (RSS)seekingalpha·26d ago·Neutral
Merck & Co., Inc. (MRK) Shareholder/Analyst Presentation - Slideshow
View source ↗ - News (Marketaux)seekingalpha.com·26d ago·Neutral
Merck & Co., Inc. (MRK) Shareholder/Analyst Presentation - Slideshow (NYSE:MRK) 2026-10-26 Merck & Co., Inc. (MRK) Shareholder/Analyst Presentation - Slideshow (NYSE:MRK) 2026-10-26
View source ↗ - Newsmarketbeat.com·27d ago·Negative
Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts Merck & Co., Inc. NYSE: MRK outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab tirumotecan, or sac-TMT, antibody-drug conjugate in endometrial cancer and its individualized neoantigen therapy, intismeran autogene, in melanoma.
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
View source ↗ - 4chan /biz/biz·27d ago·Neutral
>>62818825 >80 bill market cap >150mill revenue (which has to be split with Merck ) Good luck lol, that's 500 times SALES not earnings. good luck
View source ↗ - Newszacks.com·27d ago·Neutral
Countdown to Merck (MRK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
View source ↗ - News247wallst.com·28d ago·Negative
Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29 Merck (NYSE:MRK | MRK Price Prediction) reports third-quarter results on Thursday, Oct. 29. KEYTRUDA still anchors the business, but I'll be watching whether newer launches are growing fast enough to cushion the drug's 2028 patent loss.
View source ↗ - News (Marketaux)prnewswire.com·28d ago·Positive
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine In May 2022, the Company licensed the ex[+262 characters]
View source ↗ - News (Marketaux)manilatimes.net·29d ago·Positive
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO In May 2022, the Company licensed the ex[+262 characters]
View source ↗ - News (Marketaux)prnewswire.com·29d ago·Positive
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO In May 2022, the Company licensed the ex[+262 characters]
View source ↗ - News (RSS)seekingalpha·30d ago·Neutral
Merck/Moderna's Melanoma Combination Therapy Delivers Promising Phase 3 Trial Results
View source ↗ - News (RSS)thestreet·31d ago·Negative
Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says Moderna shares tumbled after leaked cancer vaccine trial data showed promising results for its treatment developed with Merck.
View source ↗ - News (RSS)investing·31d ago·Positive
Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall
View source ↗ - News (RSS)economictimes·31d ago·Negative
Moderna stock crashes 25%, loses about $24 billion after cancer vaccine data leak Moderna’s stock price dropped over 25% after trial results for its personalized melanoma vaccine with Merck were disclosed. The decline erased approximately $24 billion from Moderna’s market value, ending a significant rally this year. Analysts noted that this reaction was expected as investors often sell after news becomes public. Despite the drop, the trial results showed promising reductions in cancer recurrence
View source ↗ - News (RSS)fortune·31d ago·Neutral
Merck Animal Health SVP: to promote human health, invest in protecting animals While humans invest billions each year to protect ourselves from disease, less than 1% of global health spending goes toward animal health.
View source ↗ - News (RSS)zerohedge·31d ago·Negative
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight Authored by Paul D. Thacker via The DisInformation Chronicle, New York Times reporter Sheryl Gay Stolberg wrote one of the most hilarious, misleading pieces I've seen in recent months, castigating the NIH for a new vaccine injury clinic based on a leaked statement by Jack Leslie, a senior advisor to the PR firm Weber Shandwick which represents most major vaccine manufactu
View source ↗ - News (RSS)seekingalpha·34d ago·Negative
Silence Therapeutics: Downgrade To Hold On Merck KGaA Acquisition And PV siRNA
View source ↗ - Newszacks.com·34d ago·Neutral
Merck (MRK) Stock Dips While Market Gains: Key Facts In the closing of the recent trading day, Merck (MRK) stood at $143.63, denoting a -1.59% move from the preceding trading day.
View source ↗ - Newsproactiveinvestors.com·34d ago·Negative
Silence Therapeutics jumps 59% on Merck takeover Silence Therapeutics PLC (NASDAQ:SLN, FRA:XRP1, OTC:SLNCF), the clinical-stage biotechnology company, surged 59% to $6.11 after agreeing to a $1.3 billion takeover by Merck KGaA, the German pharmaceutical and technology group. Merck will pay $20 in cash for each American depositary share (ADS), representing a 130% premium to Silence's closing price on October 16 and an 82% premium to its 30-day volume-weighted average price.
View source ↗ - Newszacks.com·38d ago·Neutral
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - News (Finnhub)CNBC·39d ago·Neutral
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia area.
View source ↗ - Newszacks.com·39d ago·Neutral
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-2029.
View source ↗ - Newszacks.com·40d ago·Neutral
Merck (MRK) Dips More Than Broader Market: What You Should Know Merck (MRK) concluded the recent trading session at $141.98, signifying a -2.39% move from its prior day's close.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
New EMD Electronics Survey Highlights Capacity Challenges in the Semiconductor Industry, Points to Expanded Sustainability Drive Stronger manufacturing ecosystem required to meet AI-driven demand growth Focus on resilience vs. reshoring - avoiding single geographic or supplier dependency Sustainability is becoming an operational rather than reputational imperative SAN FRANCISCO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- SEMICON West -- EMD Electronics, the North America electronics business of Merck KGa
View source ↗ - Newsproactiveinvestors.com·41d ago·Negative
Jefferies cuts Merck's remigromig sales forecast after eye-disease trial raises concerns Jefferies has cut its peak sales forecast for Merck & Co Inc (NYSE:MRK, XETRA:6MK)'s experimental eye treatment remigromig by 60% after detailed trial results raised concerns about its efficacy and safety compared with an established rival. The US pharmaceutical company's drug met the statistical threshold for non-inferiority against Lucentis, a treatment for diabetic macular oedema, but delivered smaller nu…
View source ↗ - Newszacks.com·41d ago·Neutral
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newsgurufocus.com·43d ago·Positive
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3
View source ↗ - Newsbusinesswire.com·43d ago·Positive
…, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activ…
View source ↗ - News (RSS)zerohedge·45d ago·Neutral
Pharmaceutical Lobby Sues Over Trump Admin Program To Reduce Drug Prices Pharmaceutical Lobby Sues Over Trump Admin Program To Reduce Drug Prices Authored by Zachary Stieber via The Epoch Times, A lobbying group that represents pharmaceutical manufacturers filed suit against the federal government on Oct. 7 over a program aimed at reducing the prices of drugs. The Pharmaceutical Research and Manufacturers of America (PhRMA) stated in a legal complaint in federal court in Washington that the most
View source ↗ - Newsbarrons.com·46d ago·Negative
Merck's Keytruda Is Dealt a Legal Setback. It's Good News for This Biotech Stock. A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets.
View source ↗ - Newszacks.com·47d ago·Neutral
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know Merck (MRK) reached $141.94 at the closing of the latest trading day, reflecting a +1.72% change compared to its last close.
View source ↗ - Newszacks.com·47d ago·Positive
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? Merck's 7% dip may offer a buying opportunity as Keytruda drives growth and new products and pipeline assets strengthen its post-2028 outlook.
View source ↗ - Newszacks.com·52d ago·Neutral
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.
View source ↗ - Newsbusinesswire.com·52d ago·Neutral
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29.
View source ↗ - Newszacks.com·53d ago·Neutral
Why Merck (MRK) Dipped More Than Broader Market Today In the latest trading session, Merck (MRK) closed at $145.31, marking a -2.66% move from the previous day.
View source ↗ - Newsbenzinga.com·53d ago·Neutral
Merck Says Investigational Skin Therapy Shows Potential Merck & Co Inc. (NYSE:MRK) on Wednesday presented initial results from its Phase 2b MK-7240-012 trial at the European Academy of Dermatology and Venereology (EADV) 2026 Congress.
View source ↗ - Newszacks.com·54d ago·Neutral
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline MRK's $2.13 billion deal for SPR2015 adds a preclinical KRAS G12D inhibitor to its precision oncology pipeline, targeting a common cancer mutation.
View source ↗ - News247wallst.com·54d ago·Positive
Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Year Merck spent most of a decade trailing the S&P 500, then something unusual happened in a single year that changed the entire math.
View source ↗ - News (RSS)scmp·54d ago·Negative
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso
View source ↗ - Newszacks.com·55d ago·Neutral
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.
View source ↗ - Newsreuters.com·55d ago·Negative
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Merck said on Monday it would pay up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for rights to develop, manufacture and sell an experimental cancer treatment.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Magnetic Beads - Global Strategic Business Report: Capitalize on the Surge from $3.3 Billion in 2025 to $7.4 Billion by 2032 as Thermo Fisher Scientific, Merck KGaA, QIAGEN, Bio-Rad Laboratories and Miltenyi Biotec Battle for Leadership Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic Beads - Global Strategic Business Report" has been added to ResearchAndMarkets. com's offering. The global magnetic beads market was valued at an estimated US$3. 3 billion in 2025 and is projected to reach US$7
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Global Grignard Reagents Market Outlook and Forecast, 2026–2032 - Market to Reach USD 7.87 Billion as Safer, AI-Enabled Production Expands Opportunities for Merck KGaA, Thermo Fisher Scientific, and Tokyo Chemical Industry Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Grignard Reagents Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets. com's offering. The Grignard Reagents Market research report provides a comprehensive assessment of industry growth, production trends, appli
View source ↗ - Newsbusinesswire.com·58d ago·Neutral
…awn RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions …
View source ↗ - Newszacks.com·58d ago·Neutral
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
View source ↗ - Newsbusinesswire.com·58d ago·Neutral
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC).
View source ↗ - News (RSS)thestreet·59d ago·Negative
Bank of America has strong message for Merck stock investors A private meeting with the drugmaker's top doctor points to the next make-or-break moment for shareholders.
View source ↗ - Newsreuters.com·59d ago·Negative
Merck's eye disease drug meets main goal in trial Merck said on Thursday its drug met the main goal in a mid- to late-stage trial testing it in adult patients with a type of disease that affects blood vessels at the back of the eye.
View source ↗ - Newszacks.com·60d ago·Neutral
Merck (MRK) Declines More Than Market: Some Information for Investors In the latest trading session, Merck (MRK) closed at $148.08, marking a -1.88% move from the previous day.
View source ↗ - Newsproactiveinvestors.com·60d ago·Positive
Merck pipeline seen driving potential re-rating as clinical catalysts approach Merck & Co Inc (NYSE:MRK, XETRA:6MK) could see its shares re-rated as a series of clinical catalysts across its oncology and broader pipeline approach over the next 12 to 18 months, Bank of America (BofA) said while maintaining its 'buy' rating. The bank hosted investor meetings with Merck chief medical officer Eliav Barr, who conveyed confidence in the company's pipeline, with oncology and other programs providing mu…
View source ↗ - News (RSS)seekingalpha·61d ago·Neutral
Merck says FDA approved label update for PAH therapy Winrevair
View source ↗ - Newszacks.com·61d ago·Neutral
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
View source ↗ - Newsbusinesswire.com·61d ago·Negative
…rial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial. WINREVAIR, an activin signaling inhibitor, is FDA-approved for the …
View source ↗ - Newszacks.com·62d ago·Neutral
Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.
View source ↗ - Newsbusinesswire.com·62d ago·Negative
…a-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therap…
View source ↗
Earnings
Tue, Feb 2(in 2 months)
Consensus estimate $1.78 per share
Typical surprise +9.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$2.49 vs $2.09beat
- Tue, Aug 4$-0.13 vs $-0.27beat
- Thu, Apr 30$-1.28 vs $-1.47beat
- Tue, Feb 3$2.04 vs $2.01beat
- Thu, Oct 30$2.58 vs $2.36beat
- Tue, Jul 29$2.13 vs $2.03beat
Estimates and results for MRK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MRK officers and directors.
- Bought
- —
- Sold
- $34.2m
0 trades
14 trades
- Deluca Richard R.sold
- Guindo Chirfisold
- Zachary Jennifersold
- Deluca Richard R.sold
- Deluca Richard R.sold
- Deluca Richard R.sold
- Deluca Richard R.sold
- Deluca Richard R.sold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (38d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Buy$15,001 - $50,000
- Michael McCaulhouse · TX10 · disclosed Oct 16, 2026 (49d later)Sell$50,001 - $100,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Sell$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Oct 8, 2026 (14d later)Sell$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Sep 10, 2026 (22d later)Buy$15,001 - $50,000
- Maria Elvira Salazarhouse · FL27 · disclosed Sep 10, 2026 (22d later)Buy$15,001 - $50,000
- Maria Elvira Salazarhouse · FL27 · disclosed Sep 10, 2026 (22d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Sep 7, 2026 (31d later)Buy$15,001 - $50,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Sell$15,001 - $50,000
- Keith Selfhouse · disclosed Jul 1, 2026 (537d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Mar 17, 2026 (41d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 12, 2026 (30d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$15,001 - $50,000
- Julie Johnsonhouse · TX32 · disclosed Jan 16, 2026 (29d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 12, 2026 (24d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (27d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (29d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Sheri Biggshouse · SC03 · disclosed Oct 6, 2025 (201d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
